All eligible patients will receive SB injection therapy for 4 cycles (14\~21 days for each cycle). SB injection treatment could be continue after completion of therapy cycles until 6th cycle. It depends on the investigator's decision and patient's will. Efficacy will be evaluated every two cycles.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age of 18-70 years
Patients with histologically or cytologically confirmed Non-Small Cell Lung Cancer
Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy.
Patients with measurable lesions
Eatern Cooperative Oncolgy Group status 0 to 2.
Life expectancy \>/= 5 months
Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by
1. Absolute neutrophil count \>/= 1.5 x 10\^9/L, Platelet count \>/= 100 x 10\^9/L
2. Total bilirubin \</= upper limit of normal
3. Aspartate Aminotransferase and/or Alanine Aminotransferase \</= 2 x upeer limit of normal
4. creatinine \</= 1.5 x upeer limit of normal
Patients who have signed the informed consent form.
You may not be if
Female volunteers admitted to the study must be using a reliable means of contraception
Received radiation therapy within 6 weeks before randomization
Known brain or spinal cord metastases
Have acute infection
Have active infection or serious concomitant systemic disorder incompatible with the study
Presence or history of malignancy other than Non-Small Cell Lung Cancer
Have severe neurologic or psychological disorder
Patients who have to receive other chemo-radiotherapy or immunotherapy
Patients who have received chemotherapy within the previous 30 days
Patients who are candidates for combined modality treatment.
Patients who have participated in a clinical study within the previous 30 days
